CTXR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.43M
Średni wolumen	1.46M
Kapitalizacja rynkowa	113.82M
EPS	$0 ( 2024-05-10 )
Następna data zysków	( $-0.0500 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.00100 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Mazur Leonard L	Buy	1 165 048	Warrant to Purchase Common Stock
2024-04-03	Mazur Leonard L	Sell	1 165 048	Warrant to Purchase Common Stock
2024-04-03	Holubiak Myron Z	Buy	129 450	Warrant to Purchase Common Stock
2024-04-03	Holubiak Myron Z	Sell	129 450	Warrant to Purchase Common Stock
2024-03-14	Smith Robert Joseph	Buy	75 000	Stock Option (Right to Purchase Common Stock)

INSIDER POWER
42.17
Last 96 transactions
Buy: 27 334 255 \| Sell: 1 367 765

Wolumen Korelacja

Długi: 0.02 (neutral)

Krótki: -0.17 (neutral)

Signal:(43.053) Neutral

Citius Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
BOF	0.847
RAY	0.838

10 Najbardziej negatywne korelacje
GECCI	-0.92
MTEN	-0.886
OPTZ	-0.857
BOTT	-0.855
CCSB	-0.838

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Citius Pharmaceuticals Korelacja - Waluta/Towar

0.00
( neutral )

Citius Pharmaceuticals Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-194 316 (0.00 %)
EPS:	$-0.220

FY	2023
Przychody:	$0
Zysk brutto:	$-194 316 (0.00 %)
EPS:	$-0.220

FY	2022
Przychody:	$0
Zysk brutto:	$-179 677 (0.00 %)
EPS:	$-0.230

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Citius Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.